Geneoscopy Appoints Amit Bhalla as CFO to Drive Growth and Commercialization
Geneoscopy, Inc., a life sciences company focused on advancing gastrointestinal health through innovative diagnostic tests, has announced the appointment of Amit Bhalla as its Chief Financial Officer (CFO). With over 25 years of experience in healthcare finance, strategy, and investment, Bhalla is poised to play a key role in driving Geneoscopy’s continued growth, particularly as the company prepares for the commercial launch of ColoSense®, its RNA-based, non-invasive colorectal cancer screening test.
“Amit’s extensive financial leadership and deep understanding of the healthcare sector will be invaluable as we scale our operations and work to improve patient outcomes through innovative diagnostic solutions,” said Andrew Barnell, CEO of Geneoscopy. “Following our successful $105 million Series C financing, Amit’s expertise will help us optimize our financial strategy as we push forward with bringing ColoSense to market and advancing our pipeline of products aimed at inflammatory bowel disease (IBD).”
Bhalla joins Geneoscopy from Sampled, a global biorepository and laboratory, where he served as Executive Vice President and CFO. In this role, he led the company’s financial, supply chain, and facilities operations. Prior to his time at Sampled, Bhalla held senior roles at Becton Dickinson, serving as Vice President of Global Strategy & Development and as a member of the Executive Management Committee.
His career also spans nearly two decades on Wall Street, where he worked as a lead healthcare analyst for Lord Abbett’s Value Funds, Director of Equity Research at Citi, and Vice President at Morgan Stanley. During this time, Bhalla covered the life science tools, diagnostics, and medical device industries, gaining a wealth of experience that will benefit Geneoscopy as it expands its operations.
“This is an exciting time to join Geneoscopy’s leadership team, and I look forward to leveraging my background to support the company’s growth,” said Bhalla. “Geneoscopy is uniquely positioned to transform gastrointestinal diagnostics with its differentiated solutions, particularly in colorectal cancer screening. The company has a strong financial foundation, cutting-edge technology, and the resources to drive meaningful innovation, which makes this an ideal opportunity to make a significant impact.”
Geneoscopy is entering a crucial phase of its development with the recent $105 million Series C financing. This investment will enable the company to support the commercial launch of ColoSense, which received FDA approval in May 2024 as a non-invasive colorectal cancer screening test for average-risk adults aged 45 and older. The funding will also accelerate the company’s precision medicine approach for IBD and further advance its proprietary RNA technology platform.
ColoSense is a groundbreaking diagnostic test that uses a stool-derived eukaryotic RNA (seRNA) biomarker platform to screen for colorectal cancer and advanced adenomas. By offering a non-invasive, accurate, and patient-friendly solution, ColoSense aims to improve early detection and reduce the burden of colorectal cancer, one of the leading causes of cancer-related deaths worldwide. Geneoscopy’s approach holds the potential to transform the landscape of gastrointestinal diagnostics by offering patients and healthcare providers innovative tools for early detection and disease management.
In addition to ColoSense, Geneoscopy is developing diagnostic tests focused on treatment selection and therapy monitoring for other gastrointestinal health conditions, including IBD. The company’s partnerships with leading universities and biopharmaceutical companies are helping to accelerate the development of these diagnostic solutions, further cementing its position as a leader in the field of gastrointestinal diagnostics.
Geneoscopy’s innovative approach is grounded in its proprietary RNA-based biomarker platform, which is capable of identifying early-stage disease in a non-invasive and accurate manner. The company’s commitment to advancing gastrointestinal health through cutting-edge technology and personalized diagnostics is aligned with the growing need for more effective and accessible diagnostic solutions in this space.
With Bhalla’s appointment as CFO, Geneoscopy is well-positioned to continue its momentum and make significant strides in the commercialization of its products. His expertise in healthcare finance, strategy, and investment will be instrumental as the company navigates its next phase of growth and works to expand its impact in the gastrointestinal diagnostics field.
Geneoscopy’s mission to empower patients and providers with innovative diagnostic solutions is poised to have a lasting impact on the field of gastrointestinal health. By focusing on early detection and personalized treatment, the company aims to improve patient outcomes and provide life-changing solutions to those in need. With the leadership of Bhalla and the continued support of its investors, Geneoscopy is set to revolutionize the way gastrointestinal diseases are diagnosed and managed.
